



**Product name**      **CONCIZUMAB**  
**Labelled standard**



**Catalog number**      **COZ13241**

## Product description

CONCIZUMAB is an anti-tissue factor pathway inhibitor (TFPI) antibody in development for once-daily prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) by administration under-the-skin for all types of haemophilia. Common name Anti-TFPI, mab2021, NN7415

## mAb sequence

### Heavy chain

EVQLVESGGGLV<sup>K</sup>PGGSLR<sup>L</sup>SCAASGFTFSNYAMSWVRQ<sup>T</sup>PEKRL<sup>E</sup>WVATIS<sup>R</sup>SGSYSYFPDSV<sup>Q</sup>GRFTISR<sup>D</sup>NAKNSLY<sup>L</sup>QMNSLRAEDTAVYYCAR<sup>L</sup>GGYDEGDAMD<sup>S</sup>WGQGT<sup>T</sup>TVSSASTK<sup>G</sup>PSVFLAPCSR<sup>T</sup>SESTAALGCLV<sup>K</sup>DYFPEPVT<sup>S</sup>WNSGALTSGVHTFPAVLQSSGLYSL<sup>S</sup>VTV<sup>P</sup>SSSLG<sup>T</sup>KTYTCNV<sup>D</sup>HKPSNTK<sup>V</sup>DKR<sup>V</sup>ESKYGPPC<sup>P</sup>PCAPEFLGG<sup>P</sup>SVFLFPPK<sup>P</sup>KD<sup>T</sup>LMISR<sup>T</sup>PEVTCV<sup>V</sup>VDV<sup>S</sup>QEDPEV<sup>Q</sup>FNWYVDG<sup>V</sup>EVHNAK<sup>T</sup>KPREEQ<sup>F</sup>NSTYR<sup>V</sup>SVL<sup>T</sup>VLHQD<sup>W</sup>LNGKEYK<sup>C</sup>KVSNK<sup>G</sup>L<sup>P</sup>SSI<sup>I</sup>EKTISKAKG<sup>Q</sup>PREPQ<sup>V</sup>YTLPPSQEEM<sup>T</sup>KNQ<sup>V</sup>SLTCLV<sup>K</sup>GFY<sup>P</sup>SDIAVEWESNGQ<sup>P</sup>ENNYK<sup>T</sup>TPVL<sup>D</sup>SDG<sup>S</sup>FFLY<sup>S</sup>R<sup>L</sup>TVDK<sup>S</sup>RWQEGNVF<sup>S</sup>CSVMHEALHN<sup>H</sup>Y<sup>T</sup>QK<sup>S</sup>LSL<sup>S</sup>LGK

### Light Chain

DIVMTQ<sup>T</sup>PLSL<sup>S</sup>VTPG<sup>Q</sup>PASISCKSSQ<sup>S</sup>LSLESDG<sup>K</sup>TYLNWY<sup>L</sup>LQKPGQ<sup>S</sup>PQLLI<sup>L</sup>YLV<sup>S</sup>ILDSG<sup>V</sup>PDRFSGSG<sup>S</sup>GTDF<sup>T</sup>LKIS<sup>R</sup>VEAEDVGVYYCLQATHFPQT<sup>F</sup>GGG<sup>T</sup>KVEIK<sup>R</sup>TVAA<sup>P</sup>SVFIFPPS<sup>D</sup>EQLKSG<sup>T</sup>ASVCLLN<sup>N</sup>FYPREAK<sup>V</sup>QWKVD<sup>N</sup>ALQSG<sup>N</sup>SQES<sup>V</sup>TEQDSK<sup>D</sup>STYLS<sup>S</sup>TLT<sup>L</sup>SKADY<sup>E</sup>KHKVYACE<sup>V</sup>THQGL<sup>S</sup>SPV<sup>T</sup>K<sup>S</sup>FN<sup>R</sup>GEC

## Product features and protocols

### Key features

- 1 Purity >95%  
as determined by SDS-PAGE
- 2 Labelling Arg-<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>4</sub> | Lys-<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N<sub>2</sub>
- 3 Isotopic incorporation >98%  
as determined by LC-MS/MS analysis of digested SIL-mAb

### Other features

Expression System	CHO cell line
Protein content	Quantitation is carried out by UV Absorbance at 280 nm
Formulation	Storage buffer: 5 mM Histidine pH6 ; 60 mM trehalose ; 0.01% Polysorbate 20.

### Product preparation

We recommend the following steps:

1. Briefly centrifuge the tube before opening
2. Reconstitute by adding the appropriate volume of ultrapure water for a final concentration of 200 µg/ml (e.g. 50 µl for 10 µg or 250 µl for 50 µg)
3. Vortex gently to insure complete dissolution
4. Wait 15 minutes at room temperature before proceeding further
5. Vortex gently again and centrifuge briefly

### Product storage

The product is lyophilized and shipped at ambient temperature. Store at -80 °C upon receipt. After reconstitution, the protein can be preserved at 4°C for a few weeks.

Avoid multiple freeze-thaw cycles


## How to use our product



SIL mAbs allow to overcome the process variability since they are added at the very beginning of a sample preparation. This has positive impact on your analyte quantification, especially if the analyte interacts with other species commonly present within the matrix (1).



## Supporting information



SDS-PAGE gel analysis of CONCIZUMAB protein in non-reducing / non heated conditions (NR/NH). Stained with Coomassie blue

## References

1. G.Picard, D. Lebert, et al. PSAQ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications, J. Mass Spectrom. 2012, 47, 1353-1363



The product is intended for research use only. Not for diagnostic or therapeutic use.

## Legal

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.